Lin Bo, Zhang Tianwen, Ye Xin, Yang Hongyu
Department of Oral and Maxillofacial Surgery, Peking University Shenzhen Hospital, Shenzhen, Guangdong 518036, P.R. China.
Oncol Lett. 2020 Sep;20(3):2840-2854. doi: 10.3892/ol.2020.11841. Epub 2020 Jul 9.
Epithelial membrane protein 1 () is a key gene that regulates cell proliferation and metastatic capability in various types of cancer, and serves an important role in tumor-immune interactions. However, the association between and clinical prognosis, as well as the presence of tumor-infiltrating lymphocytes in bladder urothelial carcinoma (BLCA) remains unclear. The present study aimed to explore the relationship between expression and tumor immune cell infiltration in BLCA. In the present study, expression in BLCA was analyzed using the Oncomine database, The Cancer Genome Atlas (TCGA) and the Tumor Immune Estimation Resource (TIMER). The effects of on clinical prognosis were evaluated using the Kaplan-Meier plotter and Gene Expression Profiling Interactive Analysis. The correlations between , cancer immune infiltrates and lymphocyte abundance were determined using the TIMER and Tumor immune system interaction database. In addition, correlations between expression and gene markers in immune infiltrates were analyzed using cBioportal. The results demonstrated that, compared with adjacent normal tissues, was downregulated in BLCA tissues. High expression of was significantly associated with poor overall survival (OS) in BLCA cases obtained from TCGA. Multivariate Cox analysis revealed that was an independent predictor of OS in patients with BLCA. Gene set enrichment analysis revealed that was associated with cancer-related pathways and was positively correlated with the levels of infiltrating CD8 T cells, macrophages, neutrophils and dendritic cells in BLCA. Further analysis demonstrated that was significantly associated with the enrichment of multiple types of lymphocyte. expression exhibited a strong correlation with a range of immune markers in BLCA. In conclusion, the results of the present study demonstrated that was associated with a poor prognosis in patients with BLCA, and that the levels of immune infiltration and multiple immunomarker groups were associated with expression. These results suggested that may be used as a predictive biomarker to determine the prognosis and immune infiltration in BLCA.
上皮膜蛋白1（）是一种关键基因，可调节多种类型癌症中的细胞增殖和转移能力，并在肿瘤-免疫相互作用中发挥重要作用。然而，在膀胱尿路上皮癌（BLCA）中，其与临床预后以及肿瘤浸润淋巴细胞的存在之间的关联仍不清楚。本研究旨在探讨BLCA中该蛋白表达与肿瘤免疫细胞浸润之间的关系。在本研究中，使用Oncomine数据库、癌症基因组图谱（TCGA）和肿瘤免疫评估资源（TIMER）分析了BLCA中该蛋白的表达。使用Kaplan-Meier绘图仪和基因表达谱交互式分析评估了其对临床预后的影响。使用TIMER和肿瘤免疫系统相互作用数据库确定了该蛋白、癌症免疫浸润和淋巴细胞丰度之间的相关性。此外，使用cBioportal分析了该蛋白表达与免疫浸润中基因标志物之间的相关性。结果表明，与相邻正常组织相比，BLCA组织中该蛋白表达下调。在来自TCGA的BLCA病例中，该蛋白的高表达与较差的总生存期（OS）显著相关。多变量Cox分析显示，该蛋白是BLCA患者OS的独立预测因子。基因集富集分析显示，该蛋白与癌症相关途径有关，并且与BLCA中浸润性CD8 T细胞、巨噬细胞、中性粒细胞和树突状细胞的水平呈正相关。进一步分析表明，该蛋白与多种类型淋巴细胞的富集显著相关。在BLCA中，该蛋白表达与一系列免疫标志物表现出强烈相关性。总之，本研究结果表明，该蛋白与BLCA患者的不良预后相关，并且免疫浸润水平和多个免疫标志物组与该蛋白表达相关。这些结果表明，该蛋白可作为预测生物标志物，用于确定BLCA的预后和免疫浸润情况。
